Insider · CIK 0001235470
Christopher M Starr
Files at MNPR (Monopar Therapeutics). First filing Jul 16, 2025, latest Oct 5, 2026.
In brief
Christopher M Starr files SEC Form 4 as director at MNPR (Monopar Therapeutics). Since Jul 16, 2025, Christopher M Starr has reported 0 open-market buys worth $0 and 2 open-market sells worth $1.3M, the latest filed on Oct 5, 2026.
A track record needs three past buys with six months of prices behind them; Christopher M Starr has 0, so none is measured yet.
The newest scored trade: sold $659k of MNPR on Oct 1, 2026, filed Oct 5, 2026, scored 28 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $659k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MNPR: Monopar Therapeutics
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Monopar Therapeutics | $659k 8,400 shares | -62% | +56% from low-37% from high | |
| 70Notable | Monopar Therapeutics | $672k 16,800 shares | -76% | +1722% from low-16% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 1, 2026 | MNPR MONOPAR THERAPEUTICS INC | 16,800 0.25% of outstanding | $1.3M | Oct 1, 2026 | none |
| Jul 14, 2025 | MNPR Monopar Therapeutics | 16,800 0.27% of outstanding | $672k | Jul 14, 2025 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | MNPR Monopar Therapeutics | MOption exercise Common Stock10b5-1 | +8,400 | $0.01 | $42 | 13,573 | 9 d ago |
| Oct 1, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -4,631 | $78.09 | $362k | 8,942 | 9 d ago |
| Oct 1, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -2,970 | $78.82 | $234k | 5,972 | 9 d ago |
| Oct 1, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -799 | $79.67 | $64k | 5,173 | 9 d ago |
| Oct 1, 2026 | MNPR Monopar Therapeutics | MOption exercise Stock Optionderivative10b5-1 | -8,400 | $0.00 | $0 | 8,400 | 9 d ago |
| Dec 2, 2025 | MNPR Monopar Therapeutics | AGrant or award Stock Optionsderivative | +2,924 | $0.00 | $0 | 2,924 | Dec 8, 2025 |
| Jul 14, 2025 | MNPR Monopar Therapeutics | XIn-the-money exercise Common Stock | +16,800 | $0.01 | $84 | 21,973 | Jul 16, 2025 |
| Jul 14, 2025 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock | -16,800 | $40.00 | $672k | 5,173 | Jul 16, 2025 |
| Jul 14, 2025 | MNPR Monopar Therapeutics | XIn-the-money exercise Stock Optionsderivative | -16,800 | $0.00 | $0 | 0 | Jul 16, 2025 |
| Dec 31, 2023 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +2,533 | - | - | 25,863 | Jan 3, 2024 |
| Dec 31, 2023 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitsderivative | -2,533 | $0.00 | $0 | 0 | Jan 3, 2024 |
Questions about Christopher M Starr
Answered from the filings on this page, as of the latest one.
Is Christopher M Starr buying or selling?
In the last 12 months Christopher M Starr reported 0 open-market buys worth $0 and 1 open-market sell worth $659k on SEC Form 4; the latest was sold $659k of MNPR on Oct 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Christopher M Starr's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher M Starr has 0.
Where does Christopher M Starr file Form 4?
Christopher M Starr has filed Form 4 at MNPR (Monopar Therapeutics). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.